RNS Number: 0183L

GSK PLC 17 April 2024

GSK plc (the 'Company')Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Office	or .
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.		saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)		Ordinary shares of 31 ISIN: GB00BN7SWP6	¼ pence each ('Ordinary Shares') 33
b)	transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	770
		£16.2900	1,279
		£16.2900	1,446
d)	Aggregated information		
		3,495 £16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchai	nge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.		saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)	financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)			nterest in ADSs following the re-investment of reholders on 11 April 2024 on ADSs held in the Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$40.8000	427
d)	Aggregated information		
	Aggregated volume Price		
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	New York Stock Excl	nange (XNYS)

1.	Details of PDMR/per	son closely associated	with them ('PCA')	
a)	Name	Julie Brown		
b)	Position/status	Chief Financial Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		narket participant, auction pl	atform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D7	93	
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares'))
b)	Nature of the transaction	investment of dividends	erest in Ordinary Shares follo paid to shareholders on 11 A the Company's Deferred Annua	pril 2024 c
b)	. 10.10.10 0. 1.10	investment of dividends Ordinary Shares held in	paid to shareholders on 11 A	pril 2024 d
,	transaction	investment of dividends Ordinary Shares held in	paid to shareholders on 11 A the Company's Deferred Annua	pril 2024 c

	Aggregated volume Price	
e)	Date of the transaction	2024-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each da	e repeated for (i) each type of instrument; ate; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 3' ISIN: GB00BN7SWP	1 ¼ pence each ('Ordinary Shares') 63
b)	Nature of the transaction	investment of divider	interest in Ordinary Shares following the reds paid to shareholders on 11 April 2024 on in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	120
		£16.2900	232
		£16.2900	364
d)	Aggregated information		
	Aggregated volume Price	716 £16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Excha	nge (XLON)

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor

a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 3' ISIN: GB00BN7SWP	1/4 pence each ('Ordinary Shares') 63
b)	Nature of the transaction	investment of divider	interest in Ordinary Shares following the r ids paid to shareholders on 11 April 2024 of in the Company's Deferred Annual Bonus Pla
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	148
		£16.2900	226
		£16.2900	369
d)	Aggregated information		
	Aggregated volume Price	743 £16.2900	
e)	Date of the transaction	2024-04-16	
	Place of the		nge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communications a	nd CEO Office
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction	emission allowance market p n monitor	participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		saction; (iii) each date; and (iv	d for (i) each type of instrument; v) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence of 11 1/4 pence of 15 IN: GB00BN7SWP63	each ('Ordinary Shares')
b)	Nature of the transaction	investment of dividends paid to	o Ordinary Shares following the re- o shareholders on 11 April 2024 on npany's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	. ,	Volume(s)
		£16.2900	69
		£16.2900	141
		£16.2900	228

d)	Aggregated information	
	Aggregated volume Price	438 £16.2900
e)	Date of the transaction	2024-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/per	son closely associate	d with them ('PCA')
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Offic	er
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1 ISIN: GB00BN7SWP6	/ ₄ pence each ('Ordinary Shares') 3
b)	Nature of the transaction	investment of dividend	nterest in Ordinary Shares following the respect to shareholders on 11 April 2024 on the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.2900	253
		£16.2900	545
		£16.2900	687
d)	Aggregated information		
	Aggregated volume Price	1,485 £16.2900	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/	Initial notification

٠,	amendment	minar nonnoanon	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 on ADSs held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	\$40.8000	Volume(s)
		\$40.8000 \$40.8000	112
d)	Aggregated information		
	Aggregated volume Price	313 \$40.8000	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	New York Stock Excha	inge (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, on monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where seen conducted	
3.	(ii) each type of tra	nsaction; (iii) each date; and (iv) each place where	
	(ii) each type of tra transaction(s) has b	nsaction; (iii) each date; and (iv) each place where been conducted Ordinary shares of 31 1/4 pence each ('Ordinary Shares')	

		£16.2900	167	
		£16.2900	315	
		£16.2900	437	
			·	
d)	Aggregated information			
	Aggregated volume Price	919 £16.2900		
e)	Date of the transaction	2024-04-16		
f)	Place of the transaction	London Stock Exchan	ge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Regis Simard			
ω,	1.0	. tog.o ca.			
b)	Position/status	President, Global Suppl	y Chain		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D7	793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')		
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan			
c)	Price(s) and volume(s) Price(s)	Volume(s)	\top	
			152		
		£16.2900	132		
		£16.2900 £16.2900	253		
d)	Aggregated information	£16.2900	253		
d)		£16.2900	253		
d) e)	information Aggregated volume	£16.2900 £16.2900	253		

a)	Name	Philip Thomson		
aj	rvairie	i filip momson		
b)	Position/status	President, Global Affai	rs	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	, emission allowance market participant, auction platform, on monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D	7793	
3.		ransaction(s): section to be repeated for (i) each type of instrument; of transaction; (iii) each date; and (iv) each place where has been conducted		
a)	Description of the		/ ₄ pence each ('Ordinary Shares')	
	financial instrument	ISIN: GB00BN7SWP6	3	
b)	Nature of the transaction	Increase in notional in	nterest in Ordinary Shares following the re is paid to shareholders on 11 April 2024 or	
b)	Nature of the	Increase in notional in investment of dividend Ordinary Shares held in	nterest in Ordinary Shares following the re is paid to shareholders on 11 April 2024 or	
	Nature of the transaction	Increase in notional in investment of dividend Ordinary Shares held in	nterest in Ordinary Shares following the re s paid to shareholders on 11 April 2024 or n the Company's Deferred Annual Bonus Pla	
	Nature of the transaction	Increase in notional investment of dividend Ordinary Shares held in Price(s)	nterest in Ordinary Shares following the rest paid to shareholders on 11 April 2024 or n the Company's Deferred Annual Bonus Plat	
	Nature of the transaction	Increase in notional investment of dividend Ordinary Shares held in Price(s)	nterest in Ordinary Shares following the respective paid to shareholders on 11 April 2024 or the Company's Deferred Annual Bonus Pla Volume(s)	
	Nature of the transaction	Increase in notional investment of dividend Ordinary Shares held in Price(s) £16.2900	nterest in Ordinary Shares following the rest paid to shareholders on 11 April 2024 or in the Company's Deferred Annual Bonus Plan Volume(s) 105	
c)	Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	Increase in notional investment of dividend Ordinary Shares held in Price(s) £16.2900	nterest in Ordinary Shares following the rest paid to shareholders on 11 April 2024 or in the Company's Deferred Annual Bonus Pla Volume(s) 105	
c)	Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	Increase in notional investment of dividend Ordinary Shares held in Price(s) £16.2900 £16.2900	nterest in Ordinary Shares following the rest paid to shareholders on 11 April 2024 or in the Company's Deferred Annual Bonus Plan Volume(s) 105	

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Deborah Waterhouse		
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK		
c)	Initial notification/ amendment	Initial notification		
2.		Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		

b)	Nature of the transaction		interest in Ordinary Shares following ds paid to shareholders on 11 April 2	
			in the Company's Deferred Annual Bon	
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.2900	111	
		£16.2900	403	
		£16.2900	455	
d)	Aggregated information			
	1 1331 13111111111111111111111111111111	969 £16.2900		
e)	Date of the transaction	2024-04-16		
f)	Place of the transaction	London Stock Excha	nge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')				
a)	Name	Tc	ony Wood		
b)	Position/status	Cł	nief Scientific Officer		
c)	Initial notification/ amendment	lni	itial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	G	SK plc		
b)	LEI	54	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument		rdinary shares of 31 1/4 IN: GB00BN7SWP63	pence each ('Ordinary Shares')	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan			
c)	Price(s) and volume(s	3)	Price(s)	Volume(s)	
			£16.2900	191	
			£16.2900	561	
d)	Aggregated information	N	A (single transaction)		
d)	55 5	75	,		
d) e)	information Aggregated volume	75 £1	52		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		action(s): section to be repeated for (i) each type of instrument; asaction; (iii) each date; and (iv) each place where een conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period	
c)	Price(s) and volume(s	Price(s) Volume(s) £16.2900 6863.859	
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2024-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

DSHSFLFLWELSESL